Can you provide the last earnings date for IMMUNITYBIO INC?
IMMUNITYBIO INC (IBRX) last reported earnings on 2/23/2026.
IMMUNITYBIO INC (IBRX) Earnings History & Surprises
NASDAQ:IBRX • US45256X1037
Current stock price
7.38 USD
0 (0%)
At close:
7.3008 USD
-0.08 (-1.07%)
After Hours:
IBRX Earnings overview
Past quarterly earnings results for IMMUNITYBIO INC (IBRX), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- May 11, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.07
- Revenue Estimate
- 44.032M
Last Reported
Most Recent- Release Date
- Feb 23, 2026
- Period
- Q4 / 2025
- EPS Reported
- -$0.06
- EPS Surprise
- 37.42%
- Revenue Surprise
- 1.39%
Beat Rate
Last 8 Quarters 63%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -0.06 | -0.10 | 37.42% | 33.33% | 38.285M | 37.76M | 1.39% | 406.95% |
| Q3 2025 | -0.07 | -0.11 | 36.46% | 41.67% | 32.061M | 32.518M | -1.41% | 425.07% |
| Q2 2025 | -0.10 | -0.11 | 10.87% | 50.00% | 26.425M | 23.223M | 13.79% | 2,423.88% |
| Q1 2025 | -0.15 | -0.13 | -14.89% | 25.00% | 16.517M | 16.335M | 1.11% | 41,192.50% |
| Q4 2024 | -0.09 | -0.20 | 55.88% | 74.29% | 7.552M | 7.973M | -5.28% | 5,333.09% |
| Q3 2024 | -0.12 | -0.18 | 34.64% | 36.84% | 6.106M | 2.985M | 104.56% | 7,346.34% |
| Q2 2024 | -0.20 | -0.17 | -15.34% | 37.50% | 1.047M | 2.57M | -59.26% | 2,453.66% |
| Q1 2024 | -0.20 | -0.16 | -22.55% | 25.93% | 40K | 25.5K | 56.86% | -88.89% |
| Q4 2023 | -0.35 | -0.18 | -90.63% | -29.63% | 139K | 25.5K | 445.10% | 98.57% |
| Q3 2023 | -0.19 | -0.26 | 26.95% | 32.14% | 82K | 25.5K | 221.57% | -31.67% |
| Q2 2023 | -0.32 | -0.24 | -33.50% | -33.33% | 41K | 25.5K | 60.78% | 2.50% |
| Q1 2023 | -0.27 | -0.28 | 1.96% | -3.85% | 360K | 25.5K | 1,311.76% | 3,500.00% |
| Q4 2022 | -0.27 | -0.22 | -20.32% | -17.39% | 70K | 25.5K | 174.51% | -82.05% |
| Q3 2022 | -0.28 | -0.23 | -19.35% | -27.27% | 120K | 25.5K | 370.59% | 71.43% |
| Q2 2022 | -0.24 | -0.24 | 1.96% | -4.35% | 40K | 25.5K | 56.86% | -88.24% |
| Q1 2022 | -0.26 | -0.22 | -15.86% | -23.81% | 10K | 25.5K | -60.78% | -92.86% |
| Q4 2021 | -0.23 | -0.21 | -7.38% | 23.33% | 390K | 25.5K | 1,429.41% | 360.00% |
| Q3 2021 | -0.22 | -0.20 | -7.84% | -10.00% | 70K | 25.5K | 174.51% | -53.33% |
| Q2 2021 | -0.23 | -0.12 | -87.91% | -15.00% | 340K | 25.5K | 1,233.33% | -22.73% |
| Q1 2021 | -0.21 | -0.42 | 49.78% | -10.53% | 140K | 25.5K | 449.02% | -17.65% |
| Q4 2020 | -0.30 | -0.18 | -63.40% | - | -150K | 15.3K | -1,080.39% | - |
| Q3 2020 | -0.20 | -0.18 | -8.93% | - | 150K | 7.65K | 1,860.78% | - |
| Q2 2020 | -0.20 | -0.19 | -3.20% | - | 440K | 7.65K | 5,651.63% | - |
| Q1 2020 | -0.19 | -0.17 | -9.57% | - | 170K | - | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
3
Average EPS beat (4)
17.47%
Max EPS beat (4)
37.42%
Min EPS beat (4)
-14.89%
Revenue beat statistics
Revenue beat (4)
3
Average Revenue beat (4)
3.72%
Max Revenue beat (4)
13.79%
Min Revenue beat (4)
-1.41%
Analysis
In the last 4 quarters, IBRX has beaten EPS estimates in 3 out of 4 releases
IBRX has beaten revenue estimates in 3 out of the last 4 releases
In the last 4 quarters, IBRX has beaten the EPS estimates by 17.5% on average.
In the last 4 quarters, IBRX has beaten the revenue estimates by 3.7% on average.
Related analysis
IMMUNITYBIO INC / IBRX Earnings FAQ
Did IMMUNITYBIO INC (IBRX) beat earnings estimates last quarter?
IMMUNITYBIO INC (IBRX) beat EPS estimates and beat revenue estimates in the most recent quarter.
What percentage of the time does IBRX stock beat earnings estimates?
In the last 4 quarters, IMMUNITYBIO INC (IBRX) has beaten EPS estimates in 3 out of 4 releases.